Antimicrobial Hand Washing Products: Designed to Protect Patients, but are They Safe for Nurses?

Transcription

1 Antimicrobial Hand Washing Products: Designed to Protect Patients, but are They Safe for Nurses? Houston APIC Chapter 006 Presented by GOJO Industries GOJO Industries, Inc. All rights reserved.

2 INTRODUCTION Maria Thompson, RRT, MBA, SSBB 2

3 Why Is This an Important Topic? Current guidance around soap is limited Regulatory changes affecting soap are happening now and may be confusing for healthcare workers Product availability may be affected in the future Soap is an essential part of an effective hand hygiene regimen IPs are uniquely positioned to help their healthcare facilities interpret the coming changes and make adaptations as needed 3

4 Objectives 1. Explain the FDA Monograph and forthcoming changes. 2. Describe how the FDA and the healthcare facility will ensure safety from a nurse/healthcare worker and patient safety standpoint. 3. Review available antimicrobial ingredients and their future statuses. 4. Define important attributes of a hand hygiene product, including efficacy, skin health, and aesthetics needed to drive hand hygiene compliance. 4

5 Efficacy and RECOMMENDATIONS Around Soap 5

6 Hand Hygiene Overview Soap and Water: When hand are visibly soiled or contaminated with blood or other bodily fluids In outbreaks of C. difficile Before eating After using the restroom Alcohol-Based Hand Rub (ABHR): In all other clinical situations if hands are not visibly soiled Hand sanitizing with alcohol-based hand rub is the gold standard in all situations when hands are not visibly soiled 6 Visibly soiled = Hands on which dirt or body fluids are readily visible Hand washing represents approximately 15% of hand hygiene events in acute care facilities

7 History and Science of Soap A soap-like material found in clay cylinders during the excavation of ancient Babylon is evidence that soap making was known as early as 2800 B.C. Records show that ancient Egyptians bathed regularly The first of the famous Roman baths, supplied with water from their aqueducts, was built about 312 B.C. Traditional Soap Modern Soap Synthetic Surfactants H2O Polar Head, Hydrophilic + KOH = H2O Non-Polar Tail, Hydrophobic 7 Fat / Oil Base Micelles

8 Mechanism of Action of Soap Non-Antimicrobial Antimicrobial Removal Bacteria Surfactant Removal Antimicrobial Kill 8 Product Skin Average Log Reductions Against Bacteria After Single Wash Average Log Reductions Against C. difficile Spores After Single Wash Water Plain ~ Antimicrobial *Edmonds et. al. Infection Control and Hospital Epidemiology, March 2013, Vol. 34, No. 3

9 Non-Antimicrobial vs. Antimicrobial Soap CDC and WHO guidelines allow the use of either antimicrobial or nonantimicrobial soap There is no clinical data demonstrating a clinical benefit of antimicrobial soaps Studies are complex, expensive, longterm, difficult to control Selection based on risk profile/tolerance Estimated 60+% of soap sold in healthcare is antimicrobial Bacterial Reduction Centers for Disease Control and Prevention. Guideline for Hand Hygiene in Health-Care Settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. MMWR 2002:51 [pg 27] 9 Product Average Log Reductions Against Bacteria After Single Wash If 10,000 Bacteria on Hands, How Many CFU Remain on Hands After Hand Wash? If 1,000 Bacteria on Hands, How Many CFU Remain on Hands After Hand Wash? Water , Plain ~ Antimicrobial

10 The Effects of Different Hand Hygiene Regimens on the Reduction of Bacteria from Hands Baseline = 10,000 Bacteria After water = 1000 Bacteria (1 logs= 90%) After plain soap = 100 Bacteria (2 logs= 99%) After antimicrobial soap = 10 Bacteria (2.5-3 logs = 99.9 %) Antimicrobial soaps provide the greatest reduction of bacteria How comfortable are you leaving bacteria on healthcare workers hands? Selection based on risk profile/tolerance 10

11 11 FDA Healthcare Antiseptic Monograph

12 Over-the-Counter Drug Monograph System A drug monograph establishes conditions under which an OTC drug is GRASE (Generally Recognized as Safe and Effective) Dosage strength Dosage forms Labeling Indications Warnings Directions 12 Efficacy testing Category I GRASE Category II Not safe or not effective Category III Not enough data to determine safety or effectiveness Products containing Category I and Category III actives can be sold into the market under a Tentative Final Monograph When monograph is final, categories are replaced by terms monograph and non monograph

13 Monograph vs New Drug Application (NDA) Process MONOGRAPH A rule book listing ingredients for each therapeutic category Lists Generally Recognized As Safe and Effective (GRASE) Active ingredients: Form Dosage strength Labeling: Uses (indications) Warnings Directions Final formulation testing for some categories NEW DRUG APPLICATION (NDA) Data demonstrating that a specific formulated drug product is safe and effective for use as directed for its approved indication FDA reviews sponsor s submitted safety and efficacy data and approves the product before it can be legally sold Changes to formulation, manufacturing process, or other approved specifications must also be FDA reviewed and approved before marketing 13

14 Chlorhexidine Gluconate (CHG) and the New Drug Application (NDA) Process Chlorhexidine Gluconate introduced into the market after 1972 and therefore not eligible for inclusion in the monograph process Several CHG containing products approved for sale via NDA process for various indications Products approved through the NDA process are not subject to monograph review Safety of NDA approved products monitored through active post-marketing surveillance programs 14

15 Monograph Changes Federal Register / Vol. 59, No. 116 / Friday, June 17, 1994 / Proposed Rules DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 333 and 369 [Docket No. 75N-183H] RIN 0905-AA06 Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health- Care Antiseptic Drug Prouducts AGENCY: Food and Drug Administration, HHS. ACTION: Notice of proposed rulemaking Active Ingredient Benzalkonium Chloride (BAK) Benzethonium Chloride (BEC) Chloroxylenol (PCMX) Triclosan Chlorhexidine Gluconate (CHG) Hand Wash Application *Category III: Not enough data to make a final decision on safety and effectiveness, but sufficient data for sale of products until monograph is finalized III III III III New Drug Process 15

16 Monograph Schedule per Consent Decree Consumer Antiseptic Handwash Monograph Healthcare Antiseptic Products Monograph Consumer Antiseptic Hand Rub Products Monograph Scope Antibacterial Soaps; Residential and Away from Home settings, excluding Healthcare and Food Industry Antibacterial Soaps and Instant Hand Sanitizers in Healthcare settings only Instant Hand Sanitizers; Residential and Away from Home settings, excluding Healthcare and Food Industry Publication of TFM 12/16/2013 4/30/2015 6/30/2016 TRM Comment Period 6/16/ /31/ /31/2016 FDA Review of final data and comments 8/31/ /31/2017 3/31/2019 Final Monograph Published 9/15/2016 1/15/2018 4/15/2019 Monograph separated into two separate Consumer Monographs and a Healthcare Monograph (combines handwashes and handrubs) Healthcare facilities are unique: high risk population (patients) and dynamic reservoir of pathogenic organisms 16

17 Soap Active Ingredients Today Category III (safety and efficacy) active ingredients; Still permitted to use Final Monograph (1/15/2018) In order for an active ingredient to make the final monograph any safety / efficacy data gaps would need to be addressed (see below) Deferrals submitted for BAK, BEC, PCMX These actives have been given additional time to complete required testing Table 10. Safety Studies Available for Health Care Antiseptic Active Ingredients 1 Active Ingredient 2 Human Pharmaco - kinetic (MUsT) Animal Pharmaco - kinetic (ADME) Oral Carcinogenicity Dermal Carcinogenicity Reproductive Toxicity (DART) Potential Hormonal Effects Resistance Potential Benzalkonium Chloride Benzethonium Chloride Chloroxylenol Triclocarban Triclosan 4 Active Ingredient Benzalkonium Chloride (BAK) Benzethonium Chloride (BEC) Chloroxylenol (PCMX) Triclosan Hand Wash Application III III III III 17Empty cell indicates no data available; " " indicates incomplete data available; " " indicates available data are sufficient to make a GRAS / GRAE determination.

18 What To Expect When the Healthcare Monograph Finalizes in January 2018 Most active ingredients may be listed as Not Generally Recognized as Safe and Effective including triclosan and triclocarban. Manufacturers will have 1 year (January 2019) to stop manufacturing and distribution or reformulate healthcare antibacterial soaps containing any of these active ingredients. Deferred active ingredients will not be subject to the Final Rule and will be given extensions to allow for the submission of new safety and effectiveness data. FDA will require Industry to provide ongoing progress reports to ensure the process moves forward. 18

19 Future Monograph Implications for Healthcare Soaps Current Actives Future Actives Triclosan Triclosan Benzethonium Chloride (BEC) Benzethonium Chloride (BEC) Benzalkonium Chloride (BAK) Benzalkonium Chloride (BAK) Chloroxylenol (PCMX) Chloroxylenol (PCMX) CHG (New Drug Application) CHG (New Drug Application) Triclosan has not been granted a deferral (40% of the market today) 19

20 Key Conclusions Handwashing is an essential part of an effective hand hygiene regimen CDC and WHO do not have recommendations for the type of soap used in healthcare facilities Antimicrobial soaps provide the greatest risk reduction The FDA is finalizing its monograph; many active ingredients will be no longer available CHG is a regulatory stable option because products have been proven safe and effective by FDA Ultimately there are several critical factors that need to be considered when choosing the right soap formulation / formulations for your hospital 20

21 21 Soap Formulation and Effective Behaviors for Superior Skin Health

22 Skin Health Overview Anatomy of skin Impact of soap vs. ABHR on skin Healthcare worker perceptions of skin condition The cyclical effects of hand hygiene on skin Formulation + validation methods matter Solutions to help break the cycle of skin damage 22

23 23 Anatomy of the Skin

24 Effects on Stratum Corneum Normal Stratum Corneum Lipid Structure Moisture leaves the skin drying Allergens and pathogens enter skin dermatitis, infection Disrupted Stratum Corneum Lipid Structure 24

25 QUESTION: How many of you have talked to healthcare workers who say they do not use sanitizer because it stings and dries their hands? 25

26 The Cyclical Effects of Hand Hygiene On Skin 6 Dermatitis progress 5 Return to use Hand Wash with Soap 1 Hand Wash with Soap several times 4 Skin burns / stings as a sign of early ICD 2 ICD starts unnoticed Workplace screening for hand dermatitis: a pilot study., Occup Med Jan; Epub 2015 Sep 26., Nichol K, et. al. Hand hygiene compliance and irritant dermatitis: a juxtaposition of healthcare issues., Int J Cosmet Sci Oct, Epub 2012 Jul 5, Visscher MO1, Randall Wickett R. 3 Use of ABHR occasionally 26

27 Repetitive Exposure to Soap and Water Soap has twofold effect 1. Removes some protective natural oils with each washing 2. Once oils are removed soap reaches living cells and damages them, leading to inflammation and reduced oil production 27

28 Not all Soaps are Created Equal Soap is never meant replace ABHR But when used, it is important to select the right one It is possible to formulate a mild soap that is also efficacious 28

29 The Benefits of a Well-Formulated Product Antimicrobial Efficacy (Skin Microbiology) Skin Health (Maintain, Protect & Repair) Skin Feel (Aesthetics) User Acceptance 29

30 Skin Feel: Aesthetics and Acceptability User experience - chronic use Lather Odor (scent/fragrance) Rinsability Skin feel after use Soft, conditioned, dry, irritated, facilitates easy gloving, etc. 30

31 Learning from Biology of Skin: ph Effects Healthy skin ph is from 4.6 to 5.6 Saponified (Natural) soap ph is 9.5 to 10.5 Personal care products are formulated in a wide range of ph; ideal should mimic skin ph 31

32 Breaking the Cycle of Skin Damage Recommended Habits for Soaps Always wet hands before applying soap to skin The cooler the water the better lukewarm at most Rinse thoroughly Surfactant residue primary cause of skin irritation Gloving over surfactant residue exacerbates this issue Don t forget all areas on the hands: finger webs / knuckles Dry hands by patting, not rubbing with towels Use lotions when needed Use ABHRs whenever possible Don t forget skin care when not at work 32

33 Factors to Consider When Choosing Soap Antimicrobial vs. Non-Antimicrobial soap Regulatory stability Efficacy (for antimicrobial soaps) Skin health / mildness Skin feel / aesthetics Dispensing solutions Other value added programs 33

34 Key Conclusions Soap choice matters! Antimicrobial soaps provide the greatest risk reduction and have a history of safe use in healthcare settings There are regulatory changes coming, and you may be forced to make product changes Soap can contribute to skin damage, but this can be minimized with proper formulation and using soap when indicated Choosing a well-formulated soap can make an impact on efforts to improve hand hygiene 34

35 Objectives 1. Explain the FDA Monograph and forthcoming changes. 2. Describe how the FDA and the healthcare facility will ensure safety from a nurse/healthcare worker and patient safety standpoint. 3. Review available antimicrobial ingredients and their future statuses. 4. Define important attributes of a hand hygiene product, including efficacy, skin health, and aesthetics needed to drive hand hygiene compliance. 35

36 36 Questions and Discussion